We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+4.02%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$14.7B
AUM Growth
-$14.5M
Cap. Flow
+$16.2M
Cap. Flow %
0.11%
Top 10 Hldgs %
85.95%
Holding
111
New
8
Increased
15
Reduced
6
Closed
2

Top Buys

Rank Stock Value
1
NVTA
Invitae Corporation
NVTA
+$115M
2
IGMS
IGM Biosciences
IGMS
+$63.5M
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$47.4M
4
MYOK
MyoKardia, Inc. Common Stock
MYOK
+$26.6M
5
URGN icon
UroGen Pharma
URGN
+$24.4M

Top Sells

Rank Stock Value
1
ARRY
Array Biopharma Inc
ARRY
+$132M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$113M
3
CPRX
Catalyst Pharmaceutical
CPRX
+$6.49M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$5.15M
5
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$4.91M

Sector Composition

Rank Sector Weight
1 Healthcare 99.6%
2 Financials 0.01%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASMB icon
51
Assembly Biosciences
ASMB
$700M
$7.9M 0.05%
66,937
– –
MRKR icon
52
Marker Therapeutics
MRKR
$23.2M
$7.67M 0.05%
150,000
– –
APLS
53
DELISTED
Apellis Pharmaceuticals
APLS
$7.56M 0.05%
313,725
– –
CPRX
54
DELISTED
Catalyst Pharmaceutical
CPRX
$7.13M 0.05%
1,341,902
-1,217,559
-48% -$6.49M
HOOK
55
DELISTED
HOOKIPA Pharma
HOOK
$6.7M 0.05%
89,286
– –
ACOR
56
DELISTED
Acorda Therapeutics
ACOR
$6.41M 0.04%
18,605
+1,845
+11% +$1M
DERM
57
DELISTED
Dermira, Inc.
DERM
$5.79M 0.04%
906,943
– –
XBIT icon
58
XBiotech
XBIT
$69.5M
$5.45M 0.04%
521,327
+140,885
+37% +$1.15M
ALBO
59
DELISTED
Albireo Pharma Inc
ALBO
$5M 0.03%
250,000
– –
ARAV
60
DELISTED
Aravive, Inc. Common Stock
ARAV
$4.98M 0.03%
664,088
+179,141
+37% +$1.12M
MIST icon
61
Milestone Pharmaceuticals
MIST
$131M
$4.97M 0.03%
266,667
– –
ORTX
62
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$4.82M 0.03%
40,570
– –
HALO icon
63
Halozyme
HALO
$12.3B
$4.65M 0.03%
299,969
– –
NXTC icon
64
NextCure
NXTC
$28.8M
$4.63M 0.03%
12,500
– –
IFRX icon
65
InflaRx
IFRX
$309M
$4.39M 0.03%
+1,778,415
New +$5.17M
ANAB icon
66
AnaptysBio
ANAB
$1.71B
$3.96M 0.03%
113,086
– –
ACHN
67
DELISTED
Achillion Pharmaceuticals
ACHN
$3.94M 0.03%
1,095,359
– –
LKFT
68
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$3.83M 0.03%
25,072
– –
BLUE
69
DELISTED
bluebird bio
BLUE
$3.67M 0.03%
3,088
– –
NGM
70
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$3.46M 0.02%
250,000
– –
MIRM icon
71
Mirum Pharmaceuticals
MIRM
$5.87B
$3.35M 0.02%
+333,333
New +$4.09M
XLRN
72
DELISTED
Acceleron Pharma
XLRN
$3.31M 0.02%
83,900
– –
YARW
73
Yarrow Bioscience
YARW
$97.2M
$3.14M 0.02%
194
– –
HARP
74
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$2.93M 0.02%
21,429
– –
VKTX icon
75
Viking Therapeutics
VKTX
$3.95B
$2.92M 0.02%
425,000
– –
1 2
3
4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q3 2019 Portfolio in Review

As of Q3 2019, Julian Baker held 111 positions worth $14.7B, down 0.1% from $14.7B the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Julian Baker's Q3 2019 filing shows 8 new, 15 increased, 6 reduced and 2 closed positions. Its largest new stake was IGM Biosciences: 3,144,000 shares worth $55.8M. The largest sale was Array Biopharma Inc, an estimated $132M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials and Technology.

  • Julian Baker's largest Q3 2019 buy was IGM Biosciences: 3,144,000 shares worth $55.8M.
  • Julian Baker added most to Invitae Corporation in Q3 2019, an estimated $115M increase.
  • Julian Baker's biggest Q3 2019 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $113M.
  • Julian Baker fully exited Array Biopharma Inc in Q3 2019, selling an estimated $132M.
  • Julian Baker's ten largest holdings make up 86% of its $14.7B portfolio in Q3 2019.
  • Julian Baker opened 8 new positions and closed 2 in Q3 2019.
  • Julian Baker's portfolio value fell 0.1% quarter-over-quarter to $14.7B.

Based on Baker Bros. Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.